ClinicalTrials.gg
Active, not recruitingNCT04711135NETTER-PUpdated Feb 12, 2026Results posted

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

A Phase 2 interventional study of Lutetium [177Lu] oxodotreotide/dotatate in Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma and Paraganglioma, sponsored by Advanced Accelerator Applications. Active, not recruiting at 7 sites in 5 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Advanced Accelerator Applications (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Pheochromocytoma with a site in United States — 19 open to participants now, 28 under way, none of them phase 3. Pheochromocytoma · United States.

Enrollment
40th of 52
11 · median 31
Started
2022
the only one that year
Phase 2
30 of 69
6 open now
Primary completion
2024-03
later than 0 of 25 live
Registered
56th of 69
by date

Among the 69 studies in Pheochromocytoma with a site in United States, this one is the 40th largest by enrollment of the 52 interventional ones that give a count, is the only one that started in 2022, is one of 30 in phase 2, reaches primary completion later than 0 of the 25 other live ones, and was the 56th registered.

Pheochromocytoma

158 studies on the registry are indexed under Pheochromocytoma; 57 are open to participants now.

Browse Pheochromocytoma studies →

Open to participants now

19 of the 69 studies in Pheochromocytoma with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Pheochromocytoma studies recruiting now, 22 (51%) set no upper age limit and 6 (14%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Pheochromocytoma with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to \<18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible in the exploratory PPGL cohort.

Read the detailed description

The study schedule for each patient consists of the screening period (up to 2 weeks) followed by the treatment period (4 treatment administrations at 8-week interval), and the follow-up period (10 years).

The treatment period will consist of 4 Lutathera treatments administered at 8-week intervals. Lutathera administration will occur on Week 1 Day 1 of each cycle. Each patient will receive a total of 4 doses of Lutathera (7.4 GBq/200 mCi x 4 administrations every 8 weeks; cumulative dose: 29.6 GBq/800 mCi). An infusion of 2.5% Lysine - Arginine amino acid (AA) solution will be co-administered with each Lutathera dose for renal protection according to the approved Lutathera local prescribing information. An antiemetic will be administered prior to infusion of the AA solution for prevention of infusion-related nausea and vomiting.

The dosimetry and PK assessments will be performed during the first week after the 1st Lutathera dose, i.e. one time during the study treatment period for each patient. The dosimetry analysis will allow for estimation from the 1st Lutathera administration of the cumulative absorbed radiation dose from 4 Lutathera doses and also for taking a decision on the next dose levels. In the exceptional circumstances when dosimetry cannot be performed in a particular patient after the first Lutathera dose, it should be completed as soon as feasible upon a later dose. In order to minimize risk for each study subject, an accelerated analysis of dosimetry and safety data will be performed for each patient in the study, to enable the Investigator to take a decision for the subsequent Lutathera doses. The results of dosimetry assessments (imaging and blood dosimetry) will be provided to the investigators for their evaluation prior to administration of subsequent therapeutic cycles in each patient.

A total follow-up period of 10 years (120 months) after the last Lutathera dose will take place for each patient who received at least one dose of Lutathera. This follow-up period will be comprised of a short-term follow-up of 6 months to evaluate cumulative Lutathera toxicities, followed by a long-term follow up of another 114 months.

An external Data and Safety Monitoring Board (DSMB) will also operate in the study to evaluate accumulating safety and dosimetry data, to ensure the safety of adolescents enrolled in the study, and to provide recommendations to investigators as well as to the clinical team in charge of conducting the study.

03

Conditions studied

  • Gastroenteropancreatic Neuroendocrine Tumors
  • Pheochromocytoma
  • Paraganglioma

Keywords

  • GEP-NET
  • PPGL
  • adolescents
  • pediatric
  • Lutathera
  • Lutetium [177Lu] oxodotreotide
  • Lutetium Lu 177 dotatate
  • Peptide Receptor Radionuclide Therapy
  • PRRT
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. GEP-NET cohort: presence of metastasized or locally advanced, inoperable (curative intent), proven, G1 or G2 (Ki-67 index =\< 20%), well differentiated GEP-NET.

    or PPGL cohort: presence of metastasized or locally advanced, inoperable (curative intent), histologically proven PPGL.

  2. Patients from 12 to \< 18 years of age at the time of enrollment.
  3. Expression of somatostatin receptors confirmed by a somatostatin receptor imaging (SRI) modality within 3 months prior to enrollment, with tumor uptake observed in the target lesions more or equal to the normal liver uptake.
  4. Performance status as determined by score >= 50 or Lansky Play-Performance Scale score >= 50.
  5. Parent's ability to understand and the willingness to sign a written document for adolescents as determined by local regulations. Adolescents will sign assent along with parental/legal guardian consent or will co-sign consent with parent/legal guardian in accordance with local regulation, prior to participation in the study.

Key Exclusion Criteria:

  1. Laboratory parameters:

    1. Estimated calculated by the Cockroft-Gault method \< 70 mL/min
    2. concentration \<5.0 mmol/L (\<8.0 g/dL); WBC \<2x109/L; \<75x109/L.
    3. Total >3 x for age.
    4. Serum albumin \<3.0 g/dL unless is within the normal range.
  2. Established or suspected pregnancy.
  3. Breastfeeding female patients unless they accept to discontinue breastfeeding from the 1st dose until 3 months after the last administration of study drug.
  4. Female patients of , unless they are using highly effective methods of during treatment and for 6 months after the last dose of Lutathera.
  5. Sexually active male patients, unless they agree to remain abstinent or be willing to use effective methods of contraception.
  6. Patients for whom in the opinion of the investigator other therapeutic options are considered more appropriate than the therapy offered in the study, based on patient and disease characteristics.
  7. Current spontaneous urinary incontinence.
  8. Other known co-existing except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and proven no evidence of recurrence for 5 years.
  9. to the study drug active substance or to any of the .
  10. Patients with any other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with the completion of the study.
  11. Patient with known incompatibility to CT Scans with I.V. contrast due to allergic reaction or renal insufficiency. If such a patient can be imaged with MRI, then the patient would not be excluded.
  12. Patients who received any agent within the last 30 days.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    GEP-NET and PPGL

    All eligible participants will receive Lutathera (7.4 GBq/200 mCi x 4 administrations every 8 weeks; cumulative dose: 29.6 GBq/800 mCi), with a concomitant administration of 2.5% Lysine - Arginine amino acid solution.

    Drug: Lutetium [177Lu] oxodotreotide/dotatate

Interventions

  • DrugLutetium [177Lu] oxodotreotide/dotatate

    Drug page: Lutetium-177

    Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)

    Also known as: Lutathera

06

What researchers measure

Primary outcomes

  1. Absorbed Radiation Doses in Target Organ

    Absorbed radiation doses in target organ (e.g. kidney and bone marrow) was evaluated when all Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) and Pheochromocytoma and paraganglioma (PPGLs) as a pooled cohort patients had completed the 1st treatment of Lutathera and completed the dosimetry assessment.

    Time frame: Up to 8 days after the first Lutetium [Lu 177] dotatate dose

  2. Incidence of Adverse Events (AEs) and Lab Toxicities After 1st Lutathera Administration

    Safety in adolescents with SSTR-positive GEP-NETs and PPGLs as a pooled cohort was evaluated through the incidence of AEs and laboratory abnormalities after the first Lutathera dose.

    Time frame: during first cycle of Lutetium [Lu 177] dotatate treatment (Cycle = 56 days)

Secondary outcomes

  1. Incidence of Adverse Events (AEs) During Treatment and Short-term Follow-up

    Cumulative safety of Lutathera in adolescents with SSTR-positive GEP-NETs and PPGLs as a pooled cohort was assessed through the incidence of adverse events (AEs) and laboratory toxicities until 6 months after the last Lutathera dose.

    Time frame: From first Lutetium [Lu 177] dotatate dose to 6 months after last dose, approx. 12 months

  2. Incidence of Adverse Events (AEs) During the Long Term Follow-up

    Long-term safety of Lutathera in adolescents with SSTR-positive GEP-NETs and PPGLs as a pooled cohort was evaluated through the incidence of AEs and laboratory abnormalities during the 5-year follow-up after the last Lutathera dose.

    Time frame: Up to 5 years after the last Lutetium [Lu 177] dotatate dose

  3. Calculated Probability of Exceeding the Kidney and Bone Marrow External Beam Radiation Therapy (EBRT) Threshold

    A comparative assessment of dosimetry for organs at risk specifically kidneys and bone marrow, was performed between adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study to confirm the probability of exceeding 29 Gy (kidneys) \& 2 Gy (bone marrow) thresholds.

    Time frame: After 4 cycles of 7.4 GBq/200 mCi; each cycle is 8+/-1 weeks

  4. Pharmacokinetics (PK) Parameter: AUClast - Based on Blood Radioactivity Concentration Data

    A comparative assessment of PK will be performed between Observed and Predicted adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study. The observed PK metrics were calculated using non-compartmental analysis (NCA), the predicted PK metrics were derived based on the adolescent population pharmacokinetics (popPK) model.

    Time frame: Up to 72 hours after the first Lutetium [Lu 177] dotatate dose

  5. Pharmacokinetics (PK) Parameter: Cmax - Based on Blood Radioactivity Concentration Data

    A comparative assessment of PK will be performed between Observed and Predicted adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study. The observed PK metrics were calculated using non-compartmental analysis (NCA), the predicted PK metrics were derived based on the adolescent population pharmacokinetics (popPK) model.

    Time frame: Up to 72 hours after the first Lutetium [Lu 177] dotatate dose

  6. Pharmacokinetics (PK) Parameter: Tmax - Based on Blood Radioactivity Concentration Data

    A comparative assessment of PK will be performed between Observed and Predicted adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study. The observed PK metrics were calculated using non-compartmental analysis (NCA), the predicted PK metrics were derived based on the adolescent population pharmacokinetics (popPK) model.

    Time frame: Up to 72 hours after the first Lutetium [Lu 177] dotatate dose

07

Results

Posted Nov 27, 2024

Participant flow

At the data cut-off (DCO) date (12-Mar-2024) for this primary analysis 11 participants were enrolled across 7 centers.

Participant flow — Overall Study
MilestoneGEP-NETPPGL
Started47
Ongoing treatment01
Entered short term follow-up45
Entered long term follow-up13
Completed45
Not completed02
Withdrew: Physician decision01
Withdrew: Ongoing treatment01

Outcome measures

PrimaryAbsorbed Radiation Doses in Target Organ

Absorbed radiation doses in target organ (e.g. kidney and bone marrow) was evaluated when all Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) and Pheochromocytoma and paraganglioma (PPGLs) as a pooled cohort patients had completed the 1st treatment of Lutathera and completed the dosimetry assessment.

Time frame:
Up to 8 days after the first Lutetium [Lu 177] dotatate dose
Reported as:
Mean · Gy/GBq
Absorbed Radiation Doses in Target Organ
Gy/GBqGEP-NETPPGL
Kidney0.71 ± 0.250.82 ± 0.32
Pituitary1.2 ± 0.431.0 ± 0.45
Red Marrow (Blood)0.024 ± 0.00350.028 ± 0.0052
Red Marrow (Image)0.043 ± 0.0180.067 ± 0.028
Spleen0.63 ± 0.390.82 ± 0.17
Urinary Bladder Wall0.50 ± 0.0340.59 ± 0.096
Total Body0.040 ± 0.0130.041 ± 0.0073
PrimaryIncidence of Adverse Events (AEs) and Lab Toxicities After 1st Lutathera Administration

Safety in adolescents with SSTR-positive GEP-NETs and PPGLs as a pooled cohort was evaluated through the incidence of AEs and laboratory abnormalities after the first Lutathera dose.

Time frame:
during first cycle of Lutetium [Lu 177] dotatate treatment (Cycle = 56 days)
Reported as:
Count of participants · Participants
Incidence of Adverse Events (AEs) and Lab Toxicities After 1st Lutathera Administration
ParticipantsGEP-NETPPGL
Incidence of Adverse Events (AEs) and Lab Toxicities After 1st Lutathera Administration46
SecondaryIncidence of Adverse Events (AEs) During Treatment and Short-term Follow-up

Cumulative safety of Lutathera in adolescents with SSTR-positive GEP-NETs and PPGLs as a pooled cohort was assessed through the incidence of adverse events (AEs) and laboratory toxicities until 6 months after the last Lutathera dose.

Time frame:
From first Lutetium [Lu 177] dotatate dose to 6 months after last dose, approx. 12 months
Reported as:
Count of participants · Participants
Incidence of Adverse Events (AEs) During Treatment and Short-term Follow-up
ParticipantsGEP-NETPPGL
AEs during Lutathera treatment47
AEs during short-term follow-up13
SecondaryIncidence of Adverse Events (AEs) During the Long Term Follow-up

Long-term safety of Lutathera in adolescents with SSTR-positive GEP-NETs and PPGLs as a pooled cohort was evaluated through the incidence of AEs and laboratory abnormalities during the 5-year follow-up after the last Lutathera dose.

Time frame:
Up to 5 years after the last Lutetium [Lu 177] dotatate dose

Results for this outcome have not been posted.

SecondaryCalculated Probability of Exceeding the Kidney and Bone Marrow External Beam Radiation Therapy (EBRT) Threshold

A comparative assessment of dosimetry for organs at risk specifically kidneys and bone marrow, was performed between adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study to confirm the probability of exceeding 29 Gy (kidneys) \& 2 Gy (bone marrow) thresholds.

Time frame:
After 4 cycles of 7.4 GBq/200 mCi; each cycle is 8+/-1 weeks
Reported as:
Number · probability
Calculated Probability of Exceeding the Kidney and Bone Marrow External Beam Radiation Therapy (EBRT) Threshold
probabilityGEP-NET and PPGL
Observed: Kidney (Probability (%) >29 Gy)20.0
Observed: Bone Marrow (Probability (%) >2 Gy)0.0
SecondaryPharmacokinetics (PK) Parameter: AUClast - Based on Blood Radioactivity Concentration Data

A comparative assessment of PK will be performed between Observed and Predicted adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study. The observed PK metrics were calculated using non-compartmental analysis (NCA), the predicted PK metrics were derived based on the adolescent population pharmacokinetics (popPK) model.

Time frame:
Up to 72 hours after the first Lutetium [Lu 177] dotatate dose
Reported as:
Geometric mean · ng.h/mL
Pharmacokinetics (PK) Parameter: AUClast - Based on Blood Radioactivity Concentration Data
ng.h/mLGEP-NET and PPGL
Observed41 ± 24.15
Predicted32.34 ± 10.43
SecondaryPharmacokinetics (PK) Parameter: Cmax - Based on Blood Radioactivity Concentration Data

A comparative assessment of PK will be performed between Observed and Predicted adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study. The observed PK metrics were calculated using non-compartmental analysis (NCA), the predicted PK metrics were derived based on the adolescent population pharmacokinetics (popPK) model.

Time frame:
Up to 72 hours after the first Lutetium [Lu 177] dotatate dose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics (PK) Parameter: Cmax - Based on Blood Radioactivity Concentration Data
ng/mLGEP-NET and PPGL
Observed11.17 ± 33.04
Predicted10.31 ± 5.22
SecondaryPharmacokinetics (PK) Parameter: Tmax - Based on Blood Radioactivity Concentration Data

A comparative assessment of PK will be performed between Observed and Predicted adolescent patients with GEP-NETs and PPGLs as a pooled cohort and adult patients using the extrapolation model developed for the clinical study. The observed PK metrics were calculated using non-compartmental analysis (NCA), the predicted PK metrics were derived based on the adolescent population pharmacokinetics (popPK) model.

Time frame:
Up to 72 hours after the first Lutetium [Lu 177] dotatate dose
Reported as:
Median · hr
Pharmacokinetics (PK) Parameter: Tmax - Based on Blood Radioactivity Concentration Data
hrGEP-NET and PPGL
Observed0.58 (0.5 to 0.77)
Predicted0.5 (0.5 to 0.7)

Adverse events

Collected over AEs & on-treatment deaths were collected from the first dose of study treatment up to data cut-off date of 12-Mar-2024, approx. 19 months from the FPFV.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GEP-NET0/4 (0%)1/4 (25%)4/4 (100%)
PPGL0/7 (0%)1/7 (14.3%)7/7 (100%)
Total0/11 (0%)2/11 (18.2%)11/11 (100%)
Most frequent serious events
Most frequent serious events
EventGEP-NETPPGLTotal
Lower gastrointestinal haemorrhageGastrointestinal disorders1/40/71/11
HypercalcaemiaMetabolism and nutrition disorders1/40/71/11
Device related infectionInfections and infestations0/41/71/11
Most frequent other events
Showing 10 of 60
Most frequent other events
EventGEP-NETPPGLTotal
HeadacheNervous system disorders2/44/76/11
AnaemiaBlood and lymphatic system disorders2/42/74/11
LymphopeniaBlood and lymphatic system disorders2/42/74/11
Abdominal painGastrointestinal disorders2/41/73/11
DiarrhoeaGastrointestinal disorders2/41/73/11
EpistaxisRespiratory, thoracic and mediastinal disorders2/41/73/11
NauseaGastrointestinal disorders1/43/74/11
Lymphocyte count decreasedInvestigations0/43/73/11
NeutropeniaBlood and lymphatic system disorders1/42/73/11
VomitingGastrointestinal disorders1/42/73/11

Baseline characteristics

Full Analysis Set (FAS): The FAS included all participants that received at least one dose of Lutathera.

Age, Continuous
Age, Continuous(years)GEP-NETPPGLTotal
Mean15.5 ± 0.5814.9 ± 1.7715.1 ± 1.45
Sex: Female, Male
Sex: Female, Male(Participants)GEP-NETPPGLTotal
Female246
Male235
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GEP-NETPPGLTotal
White235
Black or African American101
Asian011
Not Reported123
Other011
08

Study locations

7 sites
09

References and documents

Publications

  • Gaze MN, Handkiewicz-Junak D, Hladun R, Laetsch TW, Sorge C, Sparks R, Wan S, Ceraulo A, Kluczewska-Galka A, Gamez-Cenzano C, States LJ, El Khouli R, Aimone P, Perraud K, Kollar G, Khanshan F, Blumenstein L, Brouri F, Giraudet AL. Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study. Eur J Nucl Med Mol Imaging. 2025 Sep;52(11):4001-4015. doi: 10.1007/s00259-025-07246-7. Epub 2025 Apr 8. PubMed 40198358 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Mar 2024, 18 months.

Results were first posted in Nov 2024, 8 months after primary completion.

Of 28 phase 2 interventional studies under Pheochromocytoma, half reached primary completion within 92 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 157. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2020
First posted
Jan 15, 2021
StartActual
Aug 31, 2022
Primary completionActual
Mar 12, 2024
CompletionEst.
Feb 6, 2034
Results first posted
Nov 27, 2024
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04711135
Responsible party
Sponsor
First posted
Jan 15, 2021
Start date
Aug 31, 2022
Primary completion
Mar 12, 2024
Completion
Feb 6, 2034 (estimated)
Results posted
Nov 27, 2024
Last update
Feb 12, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium-177

Start the discussion